Linvoseltamab with Tocilizumab for Relapsed/Refractory Multiple Myeloma
This study is looking at whether giving tocilizumab before linvoseltamab can reduce a side effect called Cytokine Release Syndrome (CRS) in people with relapsed or refractory multiple myeloma (RRMM). RRMM means your multiple myeloma has come back or hasn't responded to previous treatments. You may be able to join if you've had at least four prior treatments, including specific types of medications like a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody. The main goals are to see how often CRS occurs and how severe it is within 28 days. This study aims to understand how safe, tolerable, and effective linvoseltamab is when given after tocilizumab.
- Study design
- This is an interventional study with a planned enrollment of 30 participants. It is designed to evaluate the use of linvoseltamab and tocilizumab.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoints for this study are measured up to 28 days.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
At a glance
Conditions
Where it's being run
2 sites across 2 statesStudy leadership
- Clinical Trial Management · STUDY_DIRECTOR · Regeneron Pharmaceuticals
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Occurrence of any grade CRS per American Society for Transplantation and Cellular Therapy (ASTCT) gradingUp to 28 days
- Severity of any grade CRS per ASTCT gradingUp to 28 days